Genetic engineering of vein grafts resistant to atherosclerosis - Wikidata - awgldk - TriplyDB

Genetic engineering of vein grafts resistant to atherosclerosis

Genetic engineering of vein grafts resistant to atherosclerosis

http://www.wikidata.org/entity/Q34339752

about

Improved gene delivery to human saphenous vein cells and tissue using a peptide-modified adenoviral vector Vascular tissue engineering by computer-aided laser micromachining.Molecular advances in cardiac and cardiovascular disease.The role of preexisting pathology in the development of neointimal hyperplasia in coronary artery bypass grafts Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?Efficient gene transfer and durable transgene expression in grafted rabbit veins.Targeting the cell cycle machinery for the treatment of cardiovascular disease.Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia.Gene therapy for the extension of vein graft patency: a review.Vein graft neointimal hyperplasia is exacerbated by CXCR4 signaling in vein graft-extrinsic cells.The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.Gene therapy for the prevention of vein graft disease Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass.Gene therapy to prevent occlusion of venous bypass grafts.Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues.Coronary vein graft disease: pathogenesis and prevention.Fusigenic viral liposome for gene therapy in cardiovascular diseases.Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts.Control of cell proliferation in atherosclerosis: insights from animal models and human studies.Vein graft failure: current clinical practice and potential for gene therapeutics.Coronary artery bypass graft: why is the saphenous vein prone to intimal hyperplasia?Perivenous application of cyanoacrylate tissue sealants reduces intimal and medial thickening of the vein graft and inflammatory responses in a rabbit model of carotid artery bypass grafting.New therapeutic possibilities for vein graft disease in the post-edifoligide era.Gene therapy for cerebrovascular disease.Oligonucleotide-based gene therapy for cardiovascular disease.Vascular gene transfer.Regulation of vascular smooth muscle cell growth: targeting the final common pathway Vascular gene therapy.Gene therapy for human bypass grafts.Inhibition of anastomotic intimal hyperplasia using a chimeric decoy strategy against NFkappaB and E2F in a rabbit model.Interleukin-9 mediates chronic kidney disease-dependent vein graft disease: a role for mast cells.

P2860

Q24804662-27744736-76D4-45B5-8769-04B57D6A83A6 Q33544089-684642DC-4CD9-437C-A200-C5B98A211745 Q33641514-ED8E8248-9678-4CEF-95FF-236D8440660E Q34096919-F72C4814-62C1-4B1E-9A65-9E53D5E33475 Q34482530-C3A57468-D2BA-4576-B9CA-9F2EE5CD14F0 Q34999733-B792EFD5-619D-46AA-9E74-66DAB8202222 Q35164884-1BCE052B-53FC-484A-B34D-56A851D7AABB Q35928855-64459AB8-E0DA-4A0C-B2DF-C4382601E35E Q36032833-9207A9F7-68A5-4E84-8E8C-490BDEC86BB7 Q36339349-FD47538D-708C-4733-A0AB-57E9BC9660C8 Q36405134-78959160-639D-4E0A-A678-C191B545D07A Q36698258-89ED0D2E-8FCB-45D5-B2EF-E537D3787309 Q36962256-AF4EEF4B-90F3-4EF6-AAED-0F45A6EBEA5E Q37176430-90253C06-1102-4AAE-A3F7-58CB765E4873 Q37210126-A3E37275-CF0B-40DB-B242-9CBA5FDA074A Q37215596-A4C2E36B-7DA8-4B30-8769-35BF133549FE Q37252365-52EA2C59-EE10-4967-8504-83FEFD683B56 Q37365179-BA835323-CCE8-4AA7-A332-464F499099CA Q37630073-51346BFA-FE84-4F76-9D84-E4759AAD3D26 Q37997898-81F3365F-D4E1-4EFB-A96E-6E7DCFF8D3D1 Q38220601-FB1395BA-A41B-4C07-91E1-EB47ECC9F3D1 Q39022057-443FF2E7-BB80-4FE6-8901-FDA6C9502842 Q40311477-5D418C4B-5B22-44F0-9916-DD343596D800 Q40825648-3CB2E251-E4E1-428E-9D42-37886E3AB55C Q40836396-40766399-2A10-4972-8CD0-C7EC05C2472F Q42392222-BFF39707-8FEF-4588-BE82-078D38B3C639 Q42411623-E668A959-8F05-4574-BA96-C4274CA926DC Q45855466-EC8AD19F-74F7-42F1-9A12-A9E449AD6041 Q45877438-469F8428-4ACC-4CB9-9F37-CA1E90DF130F Q45878074-153AE588-32A6-4393-A725-71EC655C42A9 Q47630278-12B18E95-45B3-4686-B8C0-C2F09422F202

P2860

Genetic engineering of vein grafts resistant to atherosclerosis

http://www.wikidata.org/entity/Q34339752

description

1995 nî lūn-bûn

@nan

1995 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

name

Genetic engineering of vein grafts resistant to atherosclerosis

@ast

Genetic engineering of vein grafts resistant to atherosclerosis

@en

Genetic engineering of vein grafts resistant to atherosclerosis

@nl

type

label

Genetic engineering of vein grafts resistant to atherosclerosis

@ast

Genetic engineering of vein grafts resistant to atherosclerosis

@en

Genetic engineering of vein grafts resistant to atherosclerosis

@nl

prefLabel

Genetic engineering of vein grafts resistant to atherosclerosis

@ast

Genetic engineering of vein grafts resistant to atherosclerosis

@en

Genetic engineering of vein grafts resistant to atherosclerosis

@nl

P1433

Q34339752-0D2F6A65-1E9A-4468-81B1-63270598B7A6

P1476

Q34339752-ACCC5E4A-FA7D-4010-8452-01D83AE0246A

P2093

Q34339752-14A70FC9-752F-41EB-BE6D-80E88ADADF0A

Q34339752-96423156-186B-4213-98B0-A031D8EE9F4E

Q34339752-B235D28A-7ECF-46D9-B7DB-DA79CA9792BD

Q34339752-CEC275FB-8EFE-4FB0-A620-B6311425A77D

Q34339752-D9AE2567-84A7-4171-8AD6-A3492D7312AB

Q34339752-E06BC6D7-77A1-49CE-BA1F-12D1007F9443

Q34339752-EB5B493D-01FC-4611-A03E-384B4ABB6CF5

Q34339752-FF96A9EF-75A2-4FB6-A54B-DBC8FD42C73C

P2860

Q34339752-109ECF3E-672D-4A87-B74D-805112720514

Q34339752-1364C31B-8899-4010-A4D6-5777961B30F4

Q34339752-2EAE1E41-7D4E-4F5C-A50B-03077F198F39

Q34339752-3319CAB9-98B3-49D4-90E2-4F3974FB1D83

Q34339752-43616451-6F87-44EA-A196-9067F72466B1

Q34339752-64BDE0AF-59BD-44DA-867F-96211DD74FC1

Q34339752-6B274D76-9AF1-4BB2-B1B7-9170D6CF21D7

Q34339752-6F50167E-4EE7-403A-8730-04690165E664

Q34339752-75DE6AF9-64D7-4126-840D-4101569404C7

Q34339752-7B0E90A4-C39F-4571-AB48-520ED7D3D815

P304

Q34339752-EDFF8F47-F68D-43A9-9AC2-18674C92804C

P31

Q34339752-BBEFCB8C-EF5D-40C3-8731-CD61CE166467

P356

Q34339752-1018E4EF-FCEB-4A5A-8257-F89D5FB06D5C

P407

Q34339752-AD1E66F4-199E-4F8F-A635-47C6833025E0

P433

Q34339752-EDA43D43-54B0-4BDE-8DAA-36B65EFE7622

P478

Q34339752-7D899EA3-D39F-4652-B405-79554BF0A04E

P577

Q34339752-D4A9660E-22EB-4E4F-A418-128B611E5B7F

P5875

Q34339752-96499A56-2A81-429D-B076-3C02808DA7A5

P698

Q34339752-692ED2D2-6428-4F2E-BFBB-09ECBF991D79

P921

Q34339752-B3BCCAF7-E73E-4316-BFFE-C25734FC578E

P932

Q34339752-3A242DEA-CE60-401E-98DA-9609E116A6EC

P356

PNAS.92.10.4502

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Genetic engineering of vein grafts resistant to atherosclerosis

@en

P2093

F P Diet

http://www.w3.org/2001/XMLSchema#string

G H Gibbons

http://www.w3.org/2001/XMLSchema#string

J P Cooke

http://www.w3.org/2001/XMLSchema#string

M J Mann

http://www.w3.org/2001/XMLSchema#string

P S Tsao

http://www.w3.org/2001/XMLSchema#string

R S Kernoff

http://www.w3.org/2001/XMLSchema#string

V J Dzau

http://www.w3.org/2001/XMLSchema#string

Y Kaneda

http://www.w3.org/2001/XMLSchema#string

P2860

The pathogenesis of atherosclerosis: a perspective for the 1990s

Rat carotid neointimal smooth muscle cells reexpress a developmentally regulated mRNA phenotype during repair of arterial injury.

Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.

Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6.

Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II.

Smooth muscle cell hypertrophy versus hyperplasia in hypertension.

Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.

Prevention of stenosis after vascular reconstruction: pharmacologic control of intimal hyperplasia--a review.

Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries.

The future of saphenous vein as a coronary artery bypass conduit.

P304

4502-4506

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.92.10.4502

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

1995-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

15445025

http://www.w3.org/2001/XMLSchema#string

P698

7753833

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

41972

http://www.w3.org/2001/XMLSchema#string